DVT complete diagnostic approach resident survival guide: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
No edit summary |
||
Line 39: | Line 39: | ||
:No pathological evidence of IE at surgery or autopsy, with antibiotic therapy for 4 days; or | :No pathological evidence of IE at surgery or autopsy, with antibiotic therapy for 4 days; or | ||
:Does not meet criteria for possible IE as above | :Does not meet criteria for possible IE as above | ||
|- | |||
|} | |||
{| style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Management of focal atrial tachycardia}} | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Acute treatment''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left | '''''Conversion''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left | '''''Hemodynamically unstable patient''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left| ▸ '''''[[DC cardioversion]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]]) | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left | '''''Hemodynamically stable patient''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Adenosine]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR> ▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blocker]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Amiodarone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Sotalol]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Procainamide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Propafenone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]]) | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left | '''''Rate control''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blocker]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Digoxin]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]]) | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''[[SVT]] or [[atrial fibrillation]] + [[Preexcitation]]''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Ibutilide]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Procainamide]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Cardioversion]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]]) | |||
|- | |- | ||
|} | |} |
Revision as of 22:00, 8 March 2014
Probability of infective endocaritis | Characteristics |
---|---|
Definite diagnosis by pathological criteria | ❑ Microorganisms demonstrated by culture or histological examination of a vegetation, OR ❑ Pathological lesions; vegetation or intracardiac abscess confirmed by histological examination showing active endocarditis |
Definite diagnosis by clinical criteria | ❑ 2 major criteria; OR ❑ 1 major criterion and 3 minor criteria; OR |
Possible diagnosis | ❑ 1 major criterion and 1 minor criterion; OR ❑ 3 minor criteria |
Rejected diagnosis | ❑ Firm alternative diagnosis explaining evidence of IE, OR ❑ Resolution of IE syndrome with antibiotic therapy for 4 days, OR |
Criteria | Definite Infective Endocarditis According to Modified Duke Criteria |
---|---|
Pathological Criteria |
|
Clinical Criteria |
|
Possible IE |
|
Rejected |
|